The standard dosage is 5 to 10 mg per week via subcutaneous injection
Pattern 2: The Non-Responder (approximately 15% of switchers) Weight loss plateaus or slows despite escalating to Zepbound 12.5 to 15 mg May report initial response at 5 to 7.5 mg that fades by week 16 to 20 Often have underlying metabolic factors (severe insulin resistance, hypothyroidism, medications causing weight gain) For this group, the switch to tirzepatide does not solve the core problem
A dedicated MASLD trial is part of the broader TRIUMPH program
IGF-1 normalization, improved fasting insulin, and over multiple cycles, gradual shifts in markers tied to cellular aging
Because these findings are based on limited, recently published datasets with conflicting results, ongoing pharmacovigilance and large-scale prospective studies are needed
Our physicians and advanced practice clinicians (APCs) specializing in weight-loss medicine and metabolic health provide routine follow-ups along with bi-weekly lifestyle coaching to support long-term success